Invesco Dynamic Biotechnology & Genome ETF (PBE)
| Assets | $291.53M |
| NAV | $74.75 |
| Expense Ratio | 0.58% |
| PE Ratio | 49.60 |
| Shares Out | 3.90M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | Mar 23, 2020 |
| 1-Year Return | - |
| Volume | 6,587 |
| Open | 74.87 |
| Previous Close | 74.67 |
| Day's Range | 74.74 - 75.27 |
| 52-Week Low | 55.75 |
| 52-Week High | 84.86 |
| Beta | 1.05 |
| Holdings | 31 |
| Inception Date | Jun 23, 2005 |
About PBE
The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
Top 10 Holdings
44.52% of assets| Name | Symbol | Weight |
|---|---|---|
| Catalent | CTLT | 5.42% |
| Bio-Techne | TECH | 5.21% |
| Repligen | RGEN | 4.99% |
| Gilead Sciences | GILD | 4.76% |
| Amgen | AMGN | 4.73% |
| Incyte | INCY | 4.45% |
| Illumina | ILMN | 4.43% |
| Biogen | BIIB | 3.94% |
| Xencor | XNCR | 3.33% |
| Dynavax Technologies | DVAX | 3.25% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 23, 2020 | $0.02898 | Mar 31, 2020 |
| Sep 24, 2018 | $0.00207 | Sep 28, 2018 |
| Jun 16, 2017 | $0.21532 | Jun 30, 2017 |
| Mar 17, 2017 | $0.05552 | Mar 31, 2017 |
| Dec 16, 2016 | $0.1208 | Dec 30, 2016 |
| Sep 16, 2016 | $0.02834 | Sep 30, 2016 |
News
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
Biotech ETFs Benefit From Moderna Dual Booster Shot News
As the stock market attempts to reverse the recent pullback this month, Moderna shares climbed higher on Thursday after the company announced that it's creating a dual-purpose vaccine booster shot that ...
Could Biotech ETFs Get Another Boost From JNJ News?
This has been a pivotal week for biotech news, as Johnson & Johnson said Wednesday that a booster shot of its COVID-19 vaccine generated a promising immune response in early stage clinical trials. This ...
Biotech ETFs Are Already Benefitting from Pfizer Vaccine's Full Approval
There could be big gains ahead for biotech ETFs, as the Food and Drug Administration on Monday fully approved the Pfizer and BioNTech coronavirus vaccine, making it the first vaccine in the U.S. to be a...
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
Will Biotech ETFs Benefit from Biogen's New Alzheimer's Drug?
Biotech investors may have reason to celebrate this week, as the FDA approved Biogen's Alzheimer's disease drug Aducanumab on Monday, ushering in the first medication to be allowed by U.S. regulators to...
Biotech ETFs Surge on Biogen's Alzheimer Drug Approval
The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.
Play 3 Emerging ETF Trends to Follow Cathie Wood
Many would like to follow Ark Investment Management founder Cathie Wood's vision due to her success. She says that digital wallets and genomics will be the next two biggest disruptive trends after Tesla...
Biopharma Here to Stay: The Long-Term Case for the PBE ETF
The coronavirus pandemic could be a long-term positive for biopharma companies and the Invesco Dynamic Biotechnology & Genome ETF (PBE). PBE tracks the Dynamic Biotech & Genome Intellidex Index, which “...
ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion
AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.
3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexion ...
2 Biotech Funds Poised for a Healthy Breakout
Biotech stocks are likely to remain in focus through year end amid news surrounding COVID-19 vaccines and treatments.
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?
Sector ETF report for PBE
Biotech ETFs to Shine on Coronavirus Antibodies Progress
With Regeneron Pharmaceuticals and Eli Lilly & Company requesting the FDA for an Emergency Use Authorization for their antibody therapy treatments, the biotech space is filled with optimism.
Genomics ETFs Surge on Nobel Prize for Gene-Editing Pioneers
The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.
Biotech ETFs to Gain on Trump's COVID-19 Treatment Protocol
The progress in Trump's health condition and his treatment protocols are continuously under the purview of market participants and are impacting Wall Street movements.
3 Health Care ETFs Where Components Are Enduring Downgrades
After setting scintillating paces earlier this thanks to the race to develop a coronavirus vaccine, some health care exchange-traded funds are languishing.
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?
Sector ETF report for PBE
